September 4, 2021
Once a risky investment, the cannabis industry has established itself as one of the fastest-growing investment opportunities on the planet, with the sector outperforming the broader market already this year. For the first time, we are seeing a similar trajectory emerge for the psychedelic industry. Smart capital is moving in to take advantage of the opportunity to invest in the next frontier.
Full articleAugust 31, 2021
Denver activists who successfully led a 2019 campaign to make the city the first in the U.S. to decriminalize psilocybin possession have their eyes set on broader reform, with plans in the works to end the criminalization of noncommercial gifting and communal use of the psychedelic. K
Full articleAugust 23, 2021
The University of Wisconsin–Madison is launching a new research center to coordinate ongoing research and education in psychedelic compounds, as evidence grows for their utility in treating substance abuse and psychiatric disorders, such as major depression and post-traumatic stress disorder (PTSD).
Full articleAugust 12, 2021
Oregon has become the first state in the country to lay the groundwork for a therapy program that involves treatment with psilocybin, the psychoactive substance in “magic mushrooms.” The treatment will include three sessions: one for preparation, one for the “trip,” and one for reflection with a therapist. The Oregon Psilocybin Advisory Board believes the treatment could be used for anxiety, depression, and certain substance use disorders.
Full articleAugust 6, 2021
The race to provide the psychedelics industry with the cheapest and most effective psilocybin is on, and Filament Health thinks it is in the lead. The Vancouver-based psychedelic drug development company has become the first public company to receive a patent from the Canadian Intellectual Property Office for the extraction and standardization of natural psilocybin and other compounds from psychoactive mushrooms.
Full article